Press Release ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection ClearNote Health May 27, 2026
Press Release ClearNote Health to Present Early Detection Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting ClearNote Health May 22, 2026
Press Release ClearNote Health to Present Industry-Leading Early Detection Data for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026 ClearNote Health May 8, 2026
Press Release ClearNote Health to Showcase Industry-Leading Early Detection Performance of the Avantect® Pancreatic Cancer Test at AACR Annual Meeting 2026 cnhnewcorpdev April 15, 2026
Press Release ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests cnhnewcorpdev March 18, 2026
Press Release ClearNote Health’s Enhanced Avantect® Pancreatic Cancer Test Delivers Industry-Leading Early Detection Performance cnhnewcorpdev February 23, 2026
Company News Press Release ClearNote Health to Showcase Latest Advancements in Early Cancer Detection Testing at ESMO Congress 2025 cnhnewcorpdev October 17, 2025
Company News Press Release ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test cnhnewcorpdev September 25, 2025
Company News Press Release ClearNote Health Receives First In Vitro Diagnostic Approval for its Avantect® Pancreatic Cancer Test cnhnewcorpdev July 9, 2025
Company News Press Release ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients cnhnewcorpdev June 16, 2025
